4-tert-butylbenzyl ethyl ether

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-tert-butylbenzyl ethyl ether
• 英文别名: Benzene, 1-ethoxymethyl-4-tert-butyl-；1-tert-butyl-4-(ethoxymethyl)benzene
• 化学式: C₁₃H₂₀O
• 分子量: 192.301
• InChiKey: BNCMBIVYUNPQCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  乙醇 、 对叔丁基苯甲醛 在 2.7 wt% Pd/Pd(2+) (ratio 86:14) supported on TiO₂ P25 作用下， 反应 24.0h， 以53%的产率得到4-tert-butylbenzyl ethyl ether
  参考文献：
  名称：

  生物基醛光催化转移加氢的选择性控制

  摘要：

  在同一Pd/TiO 2光催化剂上，以脂肪醇为供氢体，通过光催化转移氢化，实现了生物质醛的加氢脱氧和还原醚化，选择性容易通过底物浓度进行切换。

  DOI：

  10.1002/cctc.202200120

文献信息

• Water-Soluble Calixarenes as New Inverse Phase-Transfer Catalysts. Their Scope in Aqueous Biphasic Alkylations and Mechanistic Implications
  作者：Shoichi Shimizu、Takashi Suzuki、Seiji Shirakawa、Yasuyuki Sasaki、Choichiro Hirai

  DOI：10.1002/1615-4169(200206)344:3/4<370::aid-adsc370>3.0.co;2-3

  日期：2002.6

  Alkylation reactions of active methylene compounds, alcohols and phenols with alkyl halides in aqueous NaOH solution can be carried out without the need for any added organic solvents in most cases. The water-soluble calix[n]arenes, which contain trimethylammoniomethyl groups on the upper rim, were used as inverse phase-transfer catalysts, resulting in the corresponding alkylated products in good to

  在大多数情况下，无需任何添加的有机溶剂即可在 NaOH 水溶液中进行活性亚甲基化合物、醇和酚与烷基卤化物的烷基化反应。水溶性杯[n]芳烃在上缘含有三甲基氨甲基，用作反相转移催化剂，得到相应的烷基化产物，产率从良好到高产率。讨论了该方法在水性双相烷基化反应中的范围和机理意义。
• Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
  申请人：Unoki Gen

  公开号：US20070072898A1

  公开（公告）日：2007-03-29

  A pyrazolo[1,5-a]pyridine derivative represented by formula (I) and salt thereof exhibit excellent MAPKAP-K2 inhibitory activity. Accordingly, medicines comprising this compound as an active ingredient are expected to be valuable for treating or preventing diseases mediated by MAPKAP-K2 such as inflammatory injury, autoimmune diseases, asteropathia destruens, cancer and/or growth of tumor.

  由式(I)表示的吡唑并[1,5-a]吡啶衍生物及其盐表现出优异的MAPKAP-K2抑制活性。因此，包含该化合物作为活性成分的药物预计对治疗或预防由MAPKAP-K2介导的疾病，如炎症损伤、自身免疫疾病、asteropathia destruens、癌症和/或肿瘤生长具有重要价值。
• Salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal salts of the copolymers and color-developing sheets employing the agents
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0268878A2

  公开（公告）日：1988-06-01

  Disclosed herein are salicylic acid copolymers having a weight average molecular weight of 500 10,000 and obtained (a) by condensing salicylic acid (i) with a benzyl alcohol (ii) and/or benzyl ether (iii) or a benzyl halide (iv) in the presence of an acid catalyst or (b) by reacting a co-condensation resin of (i) and (ii) and/or (iii) with (iv) or (c) by reacting a co-condensation resin of (i) and (ii) and/or (iii) or (iv) with a styrene derivative in the presence of an acid catalyst; multivalent metal salts of the salicylic acid copolymers; color-developing agents comprising the multivalent metal salts; and color-developing sheets suited for pressure-sensitive copying paper and comprising the color-developing agents. Their production processes are also disclosed.

  本文公开了水杨酸共聚物，其重量平均分子量为 500 10、000 的水杨酸共聚物；(a)在酸催化剂存在下，将水杨酸(i)与苄醇(ii)和/或苄醚(iii)或苄基卤化物(iv)缩合而得，或(b)将(i)和(ii)和/或(iii)的共缩合树脂与(iv)反应而得，或(c)在酸催化剂存在下，将(i)和(ii)和/或(iii)或(iv)的共缩合树脂与苯乙烯衍生物反应而得；水杨酸共聚物的多价金属盐；由多价金属盐组成的显色剂；以及由显色剂组成的适用于压敏复印纸的显色薄片。此外，还公开了它们的生产工艺。
• Color-developing compositions and their use
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0523697A1

  公开（公告）日：1993-01-20

  A color-developing composition comprises a multivalent-metal-modified salicylic acid resin (Resin A) and a polycondensation resin (resin B) at a weight ratio of 90-30 to 10-70. Resin A is composed of 5-35 mole% of a structural unit (I) and 65-95 mole% of at least one structural unit (II) or 65-95 mole% of a coupled structural unit of at least one unit (II) and at least one unit (III) and has a weight-average molecular weight of 350-5,000. Resin B is composed of the unit (II) and/or the unit (III) and has a weight-average molecular weight of 350-5,000. wherein Z represents M/m, M being a metal ion of m valence and m being an integer; R₁ and R₂ represent H or a C₁₋₁₂ alkyl, aralkyl, aryl or cycloalkyl group; R₃ and R₆ represent H or a C₁₋₄ alkyl group; and R₄ and R₅ represent H or CH₃.

  一种显色组合物包括一种多价金属改性水杨酸树脂（树脂 A）和一种缩聚树脂（树脂 B），两者的重量比为 90-30 比 10-70。树脂 A 由 5-35 摩尔%的结构单元（I）和 65-95 摩尔%的至少一个结构单元（II）或 65-95 摩尔%的至少一个单元（II）和至少一个单元（III）的耦合结构单元组成，其重量平均分子量为 350-5000。树脂 B 由单元（II）和/或单元（III）组成，重量平均分子量为 350-5000。 其中 Z 代表 M/m，M 为 m 价金属离子，m 为整数；R₁ 和 R₂ 代表 H 或 C₁₋₁₂ 烷基、芳基、芳烷基或环烷基；R₃ 和 R₆ 代表 H 或 C₁₋₄ 烷基；以及 R₄ 和 R₅ 代表 H 或 CH₃。
• PYRAZOLE COMPOUNDS AS BTK INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20160340339A1

  公开（公告）日：2016-11-24

  The present invention encompasses compounds of the formula (I) wherein the groups R 1 , Cy, and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.